Mineralys Therapeutics, Inc. (MLYS) PT Raised to $52 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Goldman data shows hedge funds cut leverage at fastest pace since March
Tweet
Share
E-mailGet Alerts MLYS Hot Sheet
Price: $15.55 --0%
Rating Summary:
10 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 15 | New: 12
Rating Summary:
10 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 15 | New: 12
Join SI Premium – FREE
H.C. Wainwright analyst Matthew Caufield raised the price target on Mineralys Therapeutics, Inc. (NASDAQ: MLYS) to $52.00 (from $42.00) while maintaining a Buy rating.
You May Also Be Interested In
- Rede D`Or Sao Luiz SA (RDOR3:BZ) PT Lowered to BRL44 at UBS
- Vertex (VRTX) PT Raised to $640 at UBS
- GE HealthCare (GEHC) PT Raised to $80 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
